CL2019003484A1 - Neurotoxina botulínica para el tratamiento de trastornos asociados a hiperactividad de melanocitos y/o exceso de melanina. - Google Patents

Neurotoxina botulínica para el tratamiento de trastornos asociados a hiperactividad de melanocitos y/o exceso de melanina.

Info

Publication number
CL2019003484A1
CL2019003484A1 CL2019003484A CL2019003484A CL2019003484A1 CL 2019003484 A1 CL2019003484 A1 CL 2019003484A1 CL 2019003484 A CL2019003484 A CL 2019003484A CL 2019003484 A CL2019003484 A CL 2019003484A CL 2019003484 A1 CL2019003484 A1 CL 2019003484A1
Authority
CL
Chile
Prior art keywords
melanocytes
hyperactivity
treatment
disorders associated
botulinum neurotoxin
Prior art date
Application number
CL2019003484A
Other languages
English (en)
Inventor
Birgitte P S Jacky
Shizazh Z Malik
Joanne Wang
Yi Liu
Amy Brideau-Andersen
Lance E Steward
Linh Q Le
Edward C Hsia
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2019003484A1 publication Critical patent/CL2019003484A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)

Abstract

SE PROPORCIONAN MÉTODOS PARA TRATAR AFLICCIONES DE LA PIEL RELACIONADAS CON HIPERMELANINA, COMO HIPERPIGMENTACIÓN. LOS MÉTODOS COMPRENDEN ADMINISTRAR UNA COMPOSICIÓN QUE COMPRENDE BONT/DC.
CL2019003484A 2017-05-31 2019-11-28 Neurotoxina botulínica para el tratamiento de trastornos asociados a hiperactividad de melanocitos y/o exceso de melanina. CL2019003484A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762512792P 2017-05-31 2017-05-31

Publications (1)

Publication Number Publication Date
CL2019003484A1 true CL2019003484A1 (es) 2020-05-15

Family

ID=62683456

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003484A CL2019003484A1 (es) 2017-05-31 2019-11-28 Neurotoxina botulínica para el tratamiento de trastornos asociados a hiperactividad de melanocitos y/o exceso de melanina.

Country Status (16)

Country Link
US (3) US10912823B2 (es)
EP (1) EP3630298A1 (es)
JP (1) JP7096845B2 (es)
KR (1) KR20200011499A (es)
CN (1) CN110891594A (es)
AU (1) AU2018277754A1 (es)
BR (1) BR112019025402A2 (es)
CA (1) CA3065542A1 (es)
CL (1) CL2019003484A1 (es)
CO (1) CO2019014592A2 (es)
IL (1) IL270986B (es)
MX (1) MX2019014349A (es)
PH (1) PH12019502721A1 (es)
RU (1) RU2019143639A (es)
WO (1) WO2018222652A1 (es)
ZA (1) ZA201907916B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109803673A (zh) 2016-09-13 2019-05-24 阿勒根公司 非蛋白质梭菌毒素组合物
KR20200011499A (ko) * 2017-05-31 2020-02-03 알레간 인코포레이티드 멜라닌세포 과다활성 및/또는 과량의 멜라닌과 연관된 장애 치료를 위한 보툴리눔 신경독소
KR20210097530A (ko) * 2020-01-30 2021-08-09 (주)메디톡스 Snare 복합체의 형성을 저해하는 펩티드, 및 그의 용도
KR102550756B1 (ko) * 2022-12-21 2023-07-05 (주)메디톡스 세포로부터 신경전달물질 분비를 저해하는 펩티드, 및 그의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
EP1594523B1 (en) * 2002-12-20 2009-03-25 Botulinum Toxin Research Associates, Inc. Pharmaceutical compositions comprising botulinum toxin and human serum albumin
US20060153876A1 (en) * 2003-02-24 2006-07-13 Ira Sanders Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease
US8048423B2 (en) 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
GB0820970D0 (en) * 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US9744237B2 (en) * 2009-01-29 2017-08-29 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
WO2012103415A1 (en) * 2011-01-28 2012-08-02 Allergan, Inc. Dosage regimen for the treatment of multiple disorders with botulinum toxins
US20140276359A1 (en) * 2013-03-15 2014-09-18 Plum Systems Co. Apparatus and method for tissue rejuvenation
ES2699432T3 (es) * 2013-06-28 2019-02-11 Merz Pharma Gmbh & Co Kgaa Medios y métodos para la determinación de la actividad biológica de polipéptidos de neurotoxinas en células
CN105683212B (zh) * 2013-08-21 2020-03-17 香港理工大学 高催化活性的基因改造梭菌属神经毒素
US10729896B2 (en) * 2014-09-23 2020-08-04 Avidas Pharmaceuticals Llc Delivery and induction of therapeutic agents and uses thereof
CN110198703A (zh) * 2016-11-21 2019-09-03 艾里奥治疗公司 大试剂的透皮递送
KR20200011499A (ko) * 2017-05-31 2020-02-03 알레간 인코포레이티드 멜라닌세포 과다활성 및/또는 과량의 멜라닌과 연관된 장애 치료를 위한 보툴리눔 신경독소
MX2020006424A (es) * 2017-12-20 2021-01-08 Allergan Inc Polipéptidos de dominio de unión a células de toxina botulínica y métodos de uso para el rejuvenecimiento de la piel.

Also Published As

Publication number Publication date
JP2020522492A (ja) 2020-07-30
US20210162027A1 (en) 2021-06-03
CA3065542A1 (en) 2018-12-06
AU2018277754A1 (en) 2020-01-02
US20180344820A1 (en) 2018-12-06
US10912823B2 (en) 2021-02-09
CO2019014592A2 (es) 2020-06-09
KR20200011499A (ko) 2020-02-03
MX2019014349A (es) 2020-07-28
BR112019025402A2 (pt) 2020-06-23
PH12019502721A1 (en) 2020-10-19
US20230302103A1 (en) 2023-09-28
CN110891594A (zh) 2020-03-17
RU2019143639A3 (es) 2021-09-06
EP3630298A1 (en) 2020-04-08
WO2018222652A1 (en) 2018-12-06
JP7096845B2 (ja) 2022-07-06
ZA201907916B (en) 2021-05-26
IL270986A (en) 2020-01-30
RU2019143639A (ru) 2021-06-30
IL270986B (en) 2021-07-29

Similar Documents

Publication Publication Date Title
CL2019003484A1 (es) Neurotoxina botulínica para el tratamiento de trastornos asociados a hiperactividad de melanocitos y/o exceso de melanina.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2018001897A1 (es) Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509)
CL2019000820A1 (es) Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2018002532A1 (es) Composición farmacéutica que comprende empagliflozina y sus usos
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
CR20170014A (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
BR112017012342A2 (pt) compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
BR112018001292A2 (pt) métodos para melhor liberação de agentes ativos a tumores
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
MX2018007266A (es) Combinaciones para el tratamiento del cancer.
AR097599A1 (es) Una composición que comprende extracto de guaçatonga y aroeira, su uso y un método para la prevención y/o tratamiento de señales causadas por el envejecimiento de la piel
BR112018068293A2 (pt) malassezina e seus análogos como agentes de clareamento de pele
CL2019002427A1 (es) Inhibición de smarca2 para el tratamiento de cáncer.
DOP2021000130A (es) Moduladores de la expresion de hsd17b13
BR112018002530A2 (pt) combinações e usos e tratamentos destas
PH12018500619A1 (en) A skin lightening composition comprising niacinamide and its isomers
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
CL2012001671A1 (es) Compuestos derivados de (metilsulfonil)-etil-bencenoisoindolina; composicion farmaceutica que los comprende, uso en el tratamiento del cancer, dolor, trastornos del snc, enfermedades dermatologicas, entre otras.